More than 15 million people in the United States, the United Kingdom, Germany and France do not know that they have the most aggressive forms of fatty liver disease, according to the research.
MALD-the official name of the non-alcoholic liver-in people who drink any quantities or lower alcohols that contain its liver contains more than 5 % of the fat.
It is believed that about two -thirds of patients with type 2 diabetes have a condition, which is also associated with obesity, heart and circulatory disease.
Nearly 5 % of the world’s adults have more aggressive forms than MASLD. The lipopteritis associated with the metabolic imbalance (MASH) causes fibrosis (scars) and can lead to cirrhosis and is associated with more risk of cardiovascular disease, chronic kidney disease and liver cancer.
But the vast majority of people do not know that they have the situation. An international group of researchers studied the spread and diagnosis of aggressive fatty liver in the United States, the United Kingdom, Germany and France.
Researchers have found that less than 3 % of people in the United Kingdom, France and Germany, and 4 % of those in the United States have a sheres, but diagnostic rates were less than 18 %. This means that about 20 million people in the United States, the United Kingdom, Germany and France are living with mash, but only 2.5 million people have a diagnosis, leaving more than three quarters-about 16.7 million people-unaware of their condition.
the Report, published in the regional Lancet in Europe It was shown at the Global Thinktank meeting on Lipoplasty In Barcelona, Spain calls on Thursday to double diagnostic rates from 2022 levels. Mash was diagnosed by biopsy, but now non -surgical methods such as blood, ultrasound and magnetic resonance tests can be used. As a result, every person who suffers from type 2 diabetes; Obesity along with one or more other risk factors; The researchers concluded that those who have high liver enzymes should be examined constantly for the mash.
“The costs of the non -diagrams are the economies of billions of lost productivity and poor health. Unless diagnostic rates are doubled, as well as similar increases in treatment and care, direct health costs are predicted alone over the next triple years,” said Dr. Jeffrey Lazaros, the main author of the paper and world health professor in New York and Barcelona.
“More than 15 million people across the United States and Europe have more bloody forms of fatty liver disease – they do not know this. Without a faster diagnosis and access to treatment, there is human and economic generation,” said Emmanuel Toshatzis, a professor of liver science at College University in London and a liver consultant at the Royal Hospital.
The research has also prompted renewal calls for weight loss losses to treat hormones.
“The GLP-1 (including Wegovy and Mountjaro) provides the ability to restore metabolism, by introducing the feelings of satiety-and delaying the time when the stomach takes for weight loss, thus reducing the formation of the scar tissue in the liver,” said Dr. Paul Brennan, co-author of the Lancet paper and hepatologist at NHS Tayside.
“Many people who live with type 2 or obesity are not tested for mashed until it is too late. We need it. Trials It indicates that it can benefit from multiple metabolic conditions, and improve our liver health. “
Separately Ticket It was published on Wednesday that DAPAGLIFOZIN, which reduces blood sugar levels, can also reduce fat and cirrhosis levels.
